Posted on 05/17/2018 4:18:18 AM PDT by gattaca
President Donald Trump’s new plan, “American Patients First,” is supposed to make U.S. drug prices cheaper. But the proposal isn’t expected to hurt drugmakers, middlemen or any other part of the U.S. drug supply chain, at least for now. For some players, there could be long-term concerns, including for pharmacy-benefit managers and other drug system middlemen. Many, though, had their shares surge after Trump’s speech on Friday, where he introduced the plan.
(Excerpt) Read more at marketwatch.com ...
Don’t know why the Home Industries is on the title. Shouldn’t be there.
btt
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.